Monday, January 8, 2018

Axonics Gets Marketing Nod In Australia

Irvine-based Axonics Modulation Technologies, which develops an implantable device used for treatment of overactive bladder, urinary retention, and fecal incontinence, has received approval to market its system in Australia. Axonics said the approval came from the Australian Department of Health, Therapeutic Goods Administration (TGA). Axonics is venture backed by Gilde Healthcare, CICA, Cormorant Asset Management, Edmond de Rothschild Investment Partners, Advent Life Sciences, Legend Capital, NeoMed Management, and others.